<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287909</url>
  </required_header>
  <id_info>
    <org_study_id>UFJ 2014-153</org_study_id>
    <nct_id>NCT02287909</nct_id>
  </id_info>
  <brief_title>Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease</brief_title>
  <acronym>SWAP-4</acronym>
  <official_title>Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recommended antiplatelet treatment regimen for patients affected by acute coronary&#xD;
      syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the&#xD;
      combination of aspirin and a P2Y12 receptor inhibitor. More potent P2Y12 receptor inhibitors,&#xD;
      such as ticagrelor, have been developed which are associated with less response variability&#xD;
      than clopidogrel and better clinical outcomes. Ticagrelor use has increased significantly&#xD;
      because of its more expanded Food and Drug Administration (FDA) indications compared with&#xD;
      prasugrel. However, despite the evidence for sustained efficacy and safety, many physicians&#xD;
      limit treatment duration with ticagrelor to the early phases following an ACS mostly due to&#xD;
      cost issues and concerns about increased bleeding. Therefore, it is very common in clinical&#xD;
      practice to switch patients while on maintenance dosing (MD) with ticagrelor to treatment&#xD;
      with clopidogrel. However, the pharmacodynamic (PD) effects of switching from ticagrelor to&#xD;
      clopidogrel remain unknown. Therefore, the aim of this investigation is to evaluate the PD&#xD;
      effects of switching from ticagrelor to clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recommended antiplatelet treatment regimen for patients affected by acute coronary&#xD;
      syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the&#xD;
      combination of aspirin and a P2Y12 receptor inhibitor. Currently, three P2Y12 receptor&#xD;
      inhibitors are available for clinical use (clopidogrel, prasugrel, and ticagrelor). Among&#xD;
      these, clopidogrel remains the most widely used. However, recent studies have shown that&#xD;
      there is a broad variability in platelet-inhibitory response induced by clopidogrel, which in&#xD;
      turn is associated with worse outcomes. More potent P2Y12 receptor inhibitors (prasugrel and&#xD;
      ticagrelor) have been developed which are associated with less response variability than&#xD;
      clopidogrel and better clinical outcomes. Ticagrelor use has increased significantly because&#xD;
      of its more expanded Food and Drug Administration (FDA) indications compared with prasugrel.&#xD;
      However, despite the evidence for sustained efficacy and safety, many physicians limit&#xD;
      treatment duration with ticagrelor to the early phases following an ACS (early weeks or&#xD;
      months, rather than one-year) mostly due to cost issues and concerns about increased&#xD;
      bleeding. Therefore, it is very common in clinical practice to switch patients while on&#xD;
      maintenance dosing (MD) with ticagrelor to treatment with clopidogrel. However, the&#xD;
      pharmacodynamic (PD) effects of switching from ticagrelor to clopidogrel remain unknown. In&#xD;
      addition, it is unknown whether switching from ticagrelor to clopidogrel should occur with or&#xD;
      without a loading dose (LD). Therefore, the aim of this investigation is to evaluate the PD&#xD;
      effects of switching from ticagrelor to clopidogrel with and without a LD. The present study&#xD;
      has a prospective, randomized, open-label design, in which patients will be treated with 4&#xD;
      different strategies to assess PD profiling after switching. This study will provide&#xD;
      important insights on PD effects of switching from ticagrelor to clopidogrel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity Unit</measure>
    <time_frame>48 hours after switch</time_frame>
    <description>PRU assessed by VerifyNow at 48 hours after switching of clopidogrel 600 mg LD administered 24 hours after the last ticagrelor MD vs. clopidogrel 75 mg MD given 24 hours after the last ticagrelor MD</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D) continue ticagrelor MD 90mg twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Swiching from ticagrelor to clopidogrel</description>
    <arm_group_label>A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor</arm_group_label>
    <arm_group_label>B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor</arm_group_label>
    <arm_group_label>C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Continue treatment with ticagrelor</description>
    <arm_group_label>D) continue ticagrelor MD 90mg twice daily</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients with angiographically documented CAD&#xD;
&#xD;
          2. On therapy with aspirin(&lt;100mg/day) and clopidogrel (75mg/day) for at least 30 days&#xD;
             per standard of care&#xD;
&#xD;
          3. Age between 18 and 80 years old&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. History of intracranial bleeding&#xD;
&#xD;
          2. Severe hepatic impairment (ALT &gt;2.5 times the upper limit of normal)&#xD;
&#xD;
          3. Active bleeding or propensity to bleed or blood dycrasia&#xD;
&#xD;
          4. Platelet count &lt;80x106/mL&#xD;
&#xD;
          5. Hemoglobin &lt;10g/dL&#xD;
&#xD;
          6. Hemodynamic instability&#xD;
&#xD;
          7. Estimated glomerular filtration rate (eGFR) &lt;30 mL/min&#xD;
&#xD;
          8. On treatment with oral anticoagulants&#xD;
&#xD;
          9. Patients with sick sinus syndrome (SSS) or II or III degree AV block without pacemaker&#xD;
             protection&#xD;
&#xD;
         10. Drugs interfering CYP3A4 metabolism (to avoid interaction with ticagrelor):&#xD;
             ketoconazole, itraconazole, voriconazole, clarithromicin, nefazodone, ritonavir,&#xD;
             saquinavir, nelfinavir, indinavir, atazanavir and telithromizycin&#xD;
&#xD;
         11. Pregnant females [women of childbearing age must use reliable birth control (i.e. oral&#xD;
             contraceptives) while participating in the study].&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick Angiolillo</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <results_first_submitted>July 24, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02287909/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>87 patients entered a run-in phase. Of these, 7 withdrew during run in.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A) Clopidogrel 600 mg LD 24 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="P2">
          <title>B) Clopidogrel 600 mg LD 12 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="P3">
          <title>C) Clopidogrel 75mg MD 24 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="P4">
          <title>D) Continue Ticagrelor MD 90mg Twice Daily</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Ticagrelor: Continue treatment with ticagrelor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A) Clopidogrel 600 mg LD 24 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="B2">
          <title>B) Clopidogrel 600 mg LD 12 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="B3">
          <title>C) Clopidogrel 75mg MD 24 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="B4">
          <title>D) Continue Ticagrelor MD 90mg Twice Daily</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Ticagrelor: Continue treatment with ticagrelor</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>information for each of the 4 groups and overall provided and mean and SD</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="7"/>
                    <measurement group_id="B2" value="65" spread="8"/>
                    <measurement group_id="B3" value="63" spread="9"/>
                    <measurement group_id="B4" value="58" spread="9"/>
                    <measurement group_id="B5" value="62" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet Reactivity Unit</title>
        <description>PRU assessed by VerifyNow at 48 hours after switching of clopidogrel 600 mg LD administered 24 hours after the last ticagrelor MD vs. clopidogrel 75 mg MD given 24 hours after the last ticagrelor MD</description>
        <time_frame>48 hours after switch</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Clopidogrel 600 mg LD 24 Hours After Last MD of Ticagrelor</title>
            <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>B) Clopidogrel 600 mg LD 12 Hours After Last MD of Ticagrelor</title>
            <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
          </group>
          <group group_id="O3">
            <title>C) Clopidogrel 75mg MD 24 Hours After Last MD of Ticagrelor</title>
            <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
          </group>
          <group group_id="O4">
            <title>D) Continue Ticagrelor MD 90mg Twice Daily</title>
            <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Ticagrelor: Continue treatment with ticagrelor</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Unit</title>
          <description>PRU assessed by VerifyNow at 48 hours after switching of clopidogrel 600 mg LD administered 24 hours after the last ticagrelor MD vs. clopidogrel 75 mg MD given 24 hours after the last ticagrelor MD</description>
          <units>PRU</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177" spread="27"/>
                    <measurement group_id="O2" value="164" spread="24"/>
                    <measurement group_id="O3" value="174" spread="24"/>
                    <measurement group_id="O4" value="26" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>least square mean difference</param_type>
            <param_value>-6.9</param_value>
            <ci_percent>985</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38</ci_lower_limit>
            <ci_upper_limit>24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A) Clopidogrel 600 mg LD 24 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="E2">
          <title>B) Clopidogrel 600 mg LD 12 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="E3">
          <title>C) Clopidogrel 75mg MD 24 Hours After Last MD of Ticagrelor</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Clopidogrel: Swiching from ticagrelor to clopidogrel</description>
        </group>
        <group group_id="E4">
          <title>D) Continue Ticagrelor MD 90mg Twice Daily</title>
          <description>Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily&#xD;
Ticagrelor: Continue treatment with ticagrelor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dypnea</sub_title>
                <description>Dyspnea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>BARC 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dominick J. Angiolillo, MD, PhD</name_or_title>
      <organization>University of Florida</organization>
      <phone>9042443378</phone>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

